;PMID: 2684256
;source_file_1416.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..35] = [t:0..35]
;1)sentence:[e:40..136] = [t:40..136]
;2)section:[e:140..171] = [t:140..171]
;3)section:[e:175..273] = [t:175..273]
;4)sentence:[e:277..429] = [t:277..429]
;5)sentence:[e:431..568] = [t:431..568]
;6)sentence:[e:569..780] = [t:569..780]
;7)sentence:[e:781..909] = [t:781..909]
;8)sentence:[e:910..1144] = [t:910..1144]
;9)section:[e:1148..1192] = [t:1148..1192]

;section 0 Span:0..35
;Br J Haematol  1989 Oct;73(2):165-7
(SEC
  (FRAG (NNP:[0..2] Br) (NNP:[3..4] J) (NNP:[5..13] Haematol) (CD:[15..19] 1989)
        (-LRB-:[20..27] Oct;73-LRB-) (CD:[27..28] 2) (-RRB-:[28..29] -RRB-)
        (CD:[29..33] :165) (HYPH:[33..34] -) (CD:[34..35] 7)))

;sentence 1 Span:40..136
;Co-incident N and K ras gene mutations in a case of AML, restricted to
;differing  cell lineages.
;[52..53]...[60..63]:gene-rna:"N"..."ras"
;[58..63]:gene-rna:"K ras"
;[92..95]:malignancy:"AML"
(SENT
  (NP-HLN
    (NP
      (NP
        (ADJP (AFX:[40..42] Co) (HYPH:[42..43] -) (JJ:[43..51] incident))
        (NML
          (NML
            (NML (NN:[52..53] N)
              (NML-2 (-NONE-:[53..53] *P*)))
            (NML-1 (-NONE-:[53..53] *P*)))
          (CC:[54..57] and)
          (NML
            (NML (NN:[58..59] K)
              (NML-2 (NN:[60..63] ras)))
            (NML-1 (NN:[64..68] gene) (NNS:[69..78] mutations)))))
      (PP (IN:[79..81] in)
        (NP
          (NP (DT:[82..83] a) (NN:[84..88] case))
          (PP (IN:[89..91] of)
            (NP (NN:[92..95] AML))))))
    (,:[95..96] ,)
    (VP (VBN:[97..107] restricted)
      (NP (-NONE-:[107..107] *))
      (PP (TO:[108..110] to)
        (NP (VBG:[111..120] differing) (NN:[122..126] cell)
            (NNS:[127..135] lineages))))
    (.:[135..136] .)))

;section 2 Span:140..171
;Hiorns LR, Cotter FE, Young BD.
(SEC
  (FRAG (NNP:[140..146] Hiorns) (NNP:[147..149] LR) (,:[149..150] ,)
        (NNP:[151..157] Cotter) (NNP:[158..160] FE) (,:[160..161] ,)
        (NNP:[162..167] Young) (NNP:[168..171] BD.)))

;section 3 Span:175..273
;Imperial Cancer Research Fund, Department of Medical Oncology, St
;Bartholomew's  Hospital, London.
(SEC
  (FRAG (NNP:[175..183] Imperial) (NNP:[184..190] Cancer)
        (NNP:[191..199] Research) (NNP:[200..204] Fund) (,:[204..205] ,)
        (NNP:[206..216] Department) (IN:[217..219] of) (NNP:[220..227] Medical)
        (NNP:[228..236] Oncology) (,:[236..237] ,) (NNP:[238..240] St)
        (NNP:[241..252] Bartholomew) (POS:[252..254] 's)
        (NN:[256..264] Hospital) (,:[264..265] ,) (NNP:[266..272] London)
        (.:[272..273] .)))

;sentence 4 Span:277..429
;Peripheral blood from a patient with acute myeloid leukaemia (AML) of M5 FAB 
;classification, was shown to have mutations to both the N and K ras genes.
;[314..369]:malignancy:"acute myeloid leukaemia (AML) of M5 FAB 
;classification"
;[339..342]:malignancy:"AML"
;[411..412]...[419..422]:gene-rna:"N"..."ras"
;[417..422]:gene-rna:"K ras"
(SENT
  (S
    (NP-SBJ-3
      (NP (JJ:[277..287] Peripheral) (NN:[288..293] blood))
      (PP (IN:[294..298] from)
        (NP
          (NP (DT:[299..300] a) (NN:[301..308] patient))
          (PP (IN:[309..313] with)
            (NP
              (NP
                (NP (JJ:[314..319] acute) (JJ:[320..327] myeloid)
                    (NN:[328..337] leukaemia))
                (NP (-LRB-:[338..339] -LRB-) (NN:[339..342] AML)
                    (-RRB-:[342..343] -RRB-)))
              (PP (IN:[344..346] of)
                (NP
                  (NML (NN:[347..349] M5) (NN:[350..353] FAB))
                  (NN:[355..369] classification))))))))
    (,:[369..370] ,)
    (VP (VBD:[371..374] was)
      (VP (VBN:[375..380] shown)
        (S
          (NP-SBJ-3 (-NONE-:[380..380] *))
          (VP (TO:[381..383] to)
            (VP (VB:[384..388] have)
              (NP
                (NP (NNS:[389..398] mutations))
                (PP (TO:[399..401] to)
                  (NP (CC:[402..406] both) (DT:[407..410] the)
                    (NML
                      (NML
                        (NML (NN:[411..412] N)
                          (NML-1 (-NONE-:[412..412] *P*)))
                        (NML-2 (-NONE-:[412..412] *P*)))
                      (CC:[413..416] and)
                      (NML
                        (NML (NN:[417..418] K)
                          (NML-1 (NN:[419..422] ras)))
                        (NML-2 (NNS:[423..428] genes))))))))))))
    (.:[428..429] .)))

;sentence 5 Span:431..568
;Leucophoresed blood was separated on a discontinuous Percoll density gradient
;to  provide fractions enriched for different cell lineages.
(SENT
  (S
    (NP-SBJ-1 (VBN:[431..444] Leucophoresed) (NN:[445..450] blood))
    (VP (VBD:[451..454] was)
      (VP (VBN:[455..464] separated)
        (NP-1 (-NONE-:[464..464] *))
        (PP-MNR (IN:[465..467] on)
          (NP (DT:[468..469] a) (JJ:[470..483] discontinuous)
              (NNP:[484..491] Percoll) (NN:[492..499] density)
              (NN:[500..508] gradient)))
        (S-PRP
          (NP-SBJ (-NONE-:[508..508] *))
          (VP (TO:[509..511] to)
            (VP (VB:[513..520] provide)
              (NP
                (NP (NNS:[521..530] fractions))
                (VP (VBN:[531..539] enriched)
                  (NP (-NONE-:[539..539] *))
                  (PP (IN:[540..543] for)
                    (NP (JJ:[544..553] different) (NN:[554..558] cell)
                        (NNS:[559..567] lineages))))))))))
    (.:[567..568] .)))

;sentence 6 Span:569..780
;DNA extracted from these  fractions was amplified using the polymerase chain
;reaction (PCR) technique, and  hybridized with oligonucleotide probes
;specific for the single base mutations  previously demonstrated.
;[629..639]:gene-protein:"polymerase"
;[733..754]:variation-type:"single base mutations"
(SENT
  (S
    (NP-SBJ-1
      (NP (NN:[569..572] DNA))
      (VP (VBN:[573..582] extracted)
        (NP (-NONE-:[582..582] *))
        (PP (IN:[583..587] from)
          (NP (DT:[588..593] these) (NNS:[595..604] fractions)))))
    (VP (VBD:[605..608] was)
      (VP
        (VP (VBN:[609..618] amplified)
          (NP-1 (-NONE-:[618..618] *))
          (S-MNR
            (NP-SBJ (-NONE-:[618..618] *))
            (VP (VBG:[619..624] using)
              (NP (DT:[625..628] the)
                (NML
                  (NML (NN:[629..639] polymerase) (NN:[640..645] chain)
                       (NN:[646..654] reaction))
                  (NML (-LRB-:[655..656] -LRB-) (NN:[656..659] PCR)
                       (-RRB-:[659..660] -RRB-)))
                (NN:[661..670] technique)))))
        (,:[670..671] ,) (CC:[672..675] and)
        (VP (VBN:[677..687] hybridized)
          (NP-1 (-NONE-:[687..687] *))
          (PP (IN:[688..692] with)
            (NP
              (NP (NN:[693..708] oligonucleotide) (NNS:[709..715] probes))
              (ADJP (JJ:[716..724] specific)
                (PP (IN:[725..728] for)
                  (NP
                    (NP (DT:[729..732] the)
                      
                      (NML (JJ:[733..739] single) (NN:[740..744] base))
                      (NNS:[745..754] mutations))
                    (VP (RB:[756..766] previously) (VBN:[767..779] demonstrated)
                      (NP (-NONE-:[779..779] *)))))))))))
    (.:[779..780] .)))

;sentence 7 Span:781..909
;The N-ras mutation was shown to be restricted to the  blast and monocytic
;cell fractions, concordant with the FAB subtype of M5.
;[785..790]:gene-rna:"N-ras"
(SENT
  (S
    (NP-SBJ-2 (DT:[781..784] The) (NN:[785..790] N-ras) (NN:[791..799] mutation))
    (VP (VBD:[800..803] was)
      (VP (VBN:[804..809] shown)
        (S
          (NP-SBJ-2 (-NONE-:[809..809] *))
          (VP (TO:[810..812] to)
            (VP (VB:[813..815] be)
              (ADJP-PRD (JJ:[816..826] restricted)
                (PP (TO:[827..829] to)
                  (NP (DT:[830..833] the)
                    (NML
                      (NML (NN:[835..840] blast)
                        (NML-1 (-NONE-:[840..840] *P*)))
                      (CC:[841..844] and)
                      (NML (JJ:[845..854] monocytic)
                        (NML-1 (NN:[855..859] cell) (NNS:[860..869] fractions))))))))))
        (,:[869..870] ,)
        (S-ADV
          (NP-SBJ (-NONE-:[870..870] *))
          (ADJP-PRD (JJ:[871..881] concordant)
            (PP (IN:[882..886] with)
              (NP
                (NP (DT:[887..890] the) (NN:[891..894] FAB)
                    (NN:[895..902] subtype))
                (PP (IN:[903..905] of)
                  (NP (NN:[906..908] M5)))))))))
    (.:[908..909] .)))

;sentence 8 Span:910..1144
;The  K-ras mutation, however, was present in all fractions, suggesting it had
; occurred in a multi-potential stem cell representing an earlier stage in the
; generation of the leukaemia, or possibly an incidental background
;phenomenon.
;[915..920]:gene-rna:"K-ras"
;[1085..1094]:malignancy:"leukaemia"
(SENT
  (S
    (NP-SBJ (DT:[910..913] The) (NN:[915..920] K-ras) (NN:[921..929] mutation))
    (,:[929..930] ,)
    (ADVP (RB:[931..938] however))
    (,:[938..939] ,)
    (VP (VBD:[940..943] was)
      (ADJP-PRD (JJ:[944..951] present))
      (PP-LOC (IN:[952..954] in)
        (NP (DT:[955..958] all) (NNS:[959..968] fractions)))
      (,:[968..969] ,)
      (S-ADV
        (NP-SBJ (-NONE-:[969..969] *))
        (VP (VBG:[970..980] suggesting)
          (SBAR (-NONE-:[980..980] 0)
            (S
              (NP-SBJ (PRP:[981..983] it))
              (VP (VBD:[984..987] had)
                (VP (VBN:[989..997] occurred)
                  (PP (IN:[998..1000] in)
                    (NP
                      (NP (DT:[1001..1002] a)
                        (ADJP (AFX:[1003..1008] multi) (HYPH:[1008..1009] -)
                              (NN:[1009..1018] potential))
                        (NN:[1019..1023] stem) (NN:[1024..1028] cell))
                      (VP (VBG:[1029..1041] representing)
                        (NP
                          (NP
                            (NP (DT:[1042..1044] an) (JJR:[1045..1052] earlier)
                                (NN:[1053..1058] stage))
                            (PP (IN:[1059..1061] in)
                              (NP
                                (NP (DT:[1062..1065] the)
                                    (NN:[1067..1077] generation))
                                (PP (IN:[1078..1080] of)
                                  (NP (DT:[1081..1084] the)
                                      (NN:[1085..1094] leukaemia))))))
                          (,:[1094..1095] ,) (CC:[1096..1098] or)
                          (NP
                            (ADVP (RB:[1099..1107] possibly))
                            (DT:[1108..1110] an) (JJ:[1111..1121] incidental)
                             (NN:[1122..1132] background)
                             (NN:[1133..1143] phenomenon)))))))))))))
    (.:[1143..1144] .)))

;section 9 Span:1148..1192
;PMID: 2684256 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1148..1152] PMID) (::[1152..1153] :) (CD:[1154..1161] 2684256)
        (IN:[1162..1163] -LSB-) (NNP:[1163..1169] PubMed) (HYPH:[1170..1171] -)
        (JJ:[1172..1179] indexed) (IN:[1180..1183] for)
        (NNP:[1184..1192] MEDLINE-RSB-)))
